Aziz Kabeer 4

What Happened
Aziz Kabeer, a director of AN2 Therapeutics (ANTX), had repriced option awards granted on March 19, 2026 covering a total of 44,466 underlying shares (20,724 and 23,742). The Form 4 also reports simultaneous dispositions of the same derivative amounts to the issuer. The repriced options carry an exercise price of $3.91 per share and are fully vested. The board approved the repricing on March 19, 2026.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 23, 2026 (filed within the required reporting window).
• Reported items: Two grants (code A) for 20,724 and 23,742 derivative shares and matching dispositions to the issuer (code D) for the same amounts.
• Exercise price after repricing: $3.91 per share (footnote F1).
• Option status: fully vested (footnote F2).
• Repricing approved by board on March 19, 2026; other terms unchanged except as described (footnote F3).
• Shares owned after the reported transactions: not specified in the filing.
• Transaction codes: A = award/grant of a derivative security; D = disposition to the issuer. The filing does not show a cash purchase or an open-market sale.

Context
These entries reflect a corporate compensation/option repricing event rather than an open-market buy or sale by the director. The filing does not show an exercise resulting in market sales of shares (no cashless exercise or sale to market recorded). Footnote 1 also notes a “Premium End Date” (Sept 19, 2027, change in control, or death/disability) and a provision that the exercise price could revert to the original price under certain conditions. This type of repricing is typically an administrative/compensation action and should not be read as a simple buy or sell signal.